ArticleOncology letters2026
Retrospective analysis of the association between monocyte percentage and outcomes in newly diagnosed diffuse large B-cell lymphoma.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to analyze the prognostic value of monocyte percentage (MP) at diagnosis in patients with diffuse large B-cell lymphoma (DLBCL). Overall, 169 patients with newly diagnosed DLBCL who were treated with rituximab-based therapy at the Department of Hematology, Ganzhou People's Hospital (Ganzhou, China) between January 2015 and December 2023 were retrospectively analyzed. Univariate and multivariate analyses were used to assess the impact of MP and clinical characteristics on prognosis. Kaplan-Meier curves and log-rank tests were used to analyze progression-free survival (PFS) and overall survival (OS). The prediction performance for OS was assessed using receiver operating characteristic (ROC) analysis. A total of 16 patients passed away during the follow-up, whereas 53 patients experienced disease progression/relapse. Patients were divided into groups with low (≤10%) and high (>10%) MPs, with 10% serving as the cutoff. A high MP was independently associated with worse PFS (hazard ratio, 2.54; 95% confidence interval, 1.08-5.99; P=0.033) and OS (P<0.05). When MP was combined with International Prognostic Index (IPI) scores, predictive accuracy was significantly higher than upon using IPI alone (area under the ROC curve, 0.907 vs. 0.792, respectively; P=0.043). In conclusion, in patients with DLBCL, a high MP at diagnosis is significantly associated with poor survival outcomes. Combining MP with IPI score improves prognostic stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.